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Abstract 
Background 
Computerised cognitive behaviour therapy (cCBT) for depression has the potential to be 
efficient therapy but engagement is poor in primary care trials.   
Aim 
We tested the benefits of adding telephone-support to cCBT. 
Methods 
We compared telephone-facilitated cCBT (MoodGYM) (n=187) to minimally-supported cCBT 
(MoodGYM) (n=182) in a pragmatic randomised trial (RCT).  Outcomes were depression 
severity (PHQ9), anxiety (GAD7), and somatoform complaints (PHQ15) at 4 & 12 months.   
Results 
cCBT use increased by a factor of between 1.5 and with telephone-facilitation.  At four months PHQ-
9 scores were 1.9 points lower (95% CI 0.5 to 3.3) for telephone supported cCBT.  At 12 months the 
results were no longer statistically significant (0.9 PHQ9 points; 95%CI -0.5 to 2.3).  There was 
improvement in anxiety scores and for somatic complaints. 
Discussion 
Telephone facilitation of cCBT improves engagement and expedites depression improvement.  The 
effect was small to moderate and comparable with other low intensity psychological interventions.   
Funding 
NIHR Health Technology Assessment Programme (06/43/504).  ISRCTN55310481 
Word count = 150  
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Introduction  
Depression is the most common mental health disorder in community settings and is estimated to 
become the second largest cause of global disability by 2020.1  It is one of the most common reasons 
for consulting with a primary care physician (PCP) and its associated personal and economic burden 
is considerable.2 
Whilst antidepressants remain an important treatment option, many patients and healthcare 
professionals would like to access psychological therapy as an alternative or adjunct to drug 
therapy.3  Cognitive behaviour therapy (CBT) has emerged as a leading evidence-supported form of 
brief psychological therapy for people with depression.4  However, demand for CBT cannot be met 
from existing therapist resources.5  One promising alternative to therapist-delivered CBT is the use of 
self-help interventions including the provision of therapy via computer.6  In recent years a number of 
interactive programmes have been developed which enable CBT to be delivered by computer 
(computerised CBT or cCBT).  If effective, such programmes have the potential to expand the 
provision of psychological therapy in primary care and may represent an efficient and effective form 
of care for depression.7 
In an earlier large scale pragmatic trial (the first REEACT trial)8, 9 we compared two commonly used 
cCBT packages (MoodGYM or Beating the Blues) versus usual primary care under real world 
conditions to test the effectiveness (rather than efficacy) in a pragmatic trial.  Participants were 
proactively offered technical support, and weekly encouragement to use the computer packages, 
but we purposely did not augment the content of psychological therapy over the telephone.  The 
cCBT in the first REEACT trial was therefore a form of supported self-help, but was not one which 
was guided by a clinician.  The first REEACT trial is at the time of writing the largest publicly funded 
independently-conducted primary care trial of cCBT.  The main finding of the REEACT trial was that 
for the primary outcome of depression severity at four months there was no significant benefit 
when participants were offered technically-supported cCBT in addition to usual GP care.  The most 
likely explanatory mechanism of lack of effect was poor uptake and use of computer packages by 
trial participants under real world conditions.9 
Systematic reviews have highlighted the potential for cCBT to be effective but have also further 
demonstrated variable effect sizes and substantial between-study heterogeneity.10, 11  One 
important source of between-study heterogeneity is the level of support that is made available to 
people who are offered treatment with cCBT.  Computerised CBT requires a person with depression 
to engage with a self-help computer-based technology.  Research has shown that people with 
depression often do not engage with cCBT, and only a minority actually complete all of the planned 
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sessions of the computer package.12  This observation is consistent with a broader body of research 
into the uptake and effectiveness across the range of self-help interventions for depression such as 
bibliotherapy (self-treatment using written materials).13  Research in the area of self-help treatments 
for depression has demonstrated that entirely self-guided materials (with no professional support) 
are likely to be less effective than self-help technologies where there is a level of guidance and 
professional support (‘guided self-help’).  Unsupported self-help treatment (including unsupported 
computer-delivered self-help) has been shown in systematic reviews to have minimal or relatively 
small effect sizes.13  In contrast, more intensively- and professionally-supported treatments have 
generally been found in efficacy trials to have moderate effect sizes claimed to be comparable to 
those achieved with face-to-face therapy.14  To our knowledge the comparative effectiveness of 
minimally-supported cCBT versus more intensively supported cCBT has not been directly tested in 
large-scale, independently-conducted, head-to-head, pragmatic trials (though there are some head 
to head comparisons in smaller-scale trials 15). 
We postulated on the basis of these findings, and on the basis of emerging trial-based evidence 
summarised in systematic reviews (e.g. 10) that people with depression might engage with cCBT and 
it might show an effect, but only if offered alongside a high level of facilitation and support.  We 
designed the present study (the REEACT 2 trial) to test this hypothesis and to generate trial-based 
evidence on the best means of delivering cCBT in primary care mental health services. 
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Methods 
Study design and patients 
The second Randomised Evaluation of Effectiveness and Acceptability of Computer-delivered 
Therapy (REEACT 2) trial was designed to examine the additional benefits of telephone-facilitation 
and structured guidance alongside a free to use computer-delivered CBT package (MoodGYM).  The 
comparator was minimally-supported cCBT.   
Participants in both arms were given access to a free-to-use cCBT programme (MoodGYM), an 
accompanying booklet, a Freephone number for technical support and continued with usual GP care.  
MoodGYM (©ANU http://moodgym.anu.edu.au) is a free-to-use, internet-based, interactive CBT 
programme for depression developed and copyrighted at the Australian National University Centre 
for Mental Health Research.  The online programme is accompanied by a booklet with exercises and 
quizzes and consists of five interactive modules released sequentially and lasting approximately 30-
45 minutes and a sixth session that is predominantly consolidation and revision.  Study participants 
were asked to complete one session each week.  The programme provides patients with CBT 
techniques to overcome patterns of unhelpful thinking using cartoon characters to represent habits 
of thought.  
Experimental arm: Participants in the telephone-facilitated cCBT (experimental) arm were allocated 
a telephone support worker (TSW) who provided a programme of weekly telephone calls.  The 
background of TSWs was that of a graduate-level support worker.  The telephone facilitation 
programme comprised eight telephone calls to be completed alongside the cCBT programme within 
14 weeks of first contact from the telephone support worker (and before the four-month follow-up 
time point).  The purpose of the first and longest session (30-40 minutes) was to introduce the 
participant to the principles of CBT and the MoodGYM programme and booklet, explain the process 
and help the participant identify difficulties and goals, and feel confident about engaging with the 
intervention.  The following six sessions were between 10 and 20 minutes long and were intended to 
provide motivation and to help participants identify any barriers to engagement with cCBT and to 
the achievement of their goal(s).  The final session helped participants to consolidate what they had 
learned from cCBT and discuss their next steps and, if appropriate, how they might use the 
MoodGYM programme in the future.  The telephone facilitation programme was delivered according 
to a manual developed by co-investigator KL in conjunction with the REEACT-2 team.  TSWs received 
one day of training in the delivery of the intervention.  Clinical supervision was given to trial 
telephone support workers by investigators KL, DK and SG. 
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Comparator arm:  All participants in the control group were registered as users of MoodGYM and 
given a unique password.  As with the intervention group, they were supplied with a free helpline 
number to ring if they had technical problems or needed advice and a booklet explaining MoodGYM, 
but they did not receive regular phone calls.  This comparator intervention replicated United 
Kingdom National Health Services (NHS) care in most settings and represented what would happen if 
a patient were given the website of a cCBT package such as MoodGYM by their primary care 
physician or primary care mental health worker without being offered pro-active support. 
The study population comprised patients selected from primary care with depression or low mood 
as determined by a score of ten or more on the Patient Health Questionnaire (PHQ-9).16  This cut-off 
point is known to detect clinical depression (major depression) in a primary care populations17 with 
acceptable sensitivity and specificity.  The REEACT 2 participants were recruited from a mix of rural 
and urban UK primary care practices in and around Bristol, Avon, Somerset, Gloucestershire, 
Manchester, Sheffield, Derbyshire, South Yorkshire, Humberside, East Yorkshire, Durham, Tyneside 
and Northumberland. 
Participants meeting the following criteria were eligible to enter the study: 
• Aged 18 or above 
• Not currently in receipt of cCBT or specialist psychological therapy 
• Score of ≥10 overall (indicating moderate, moderately severe or severe depression) and <3 
for question 9 (measuring suicidal thoughts) on the PHQ-9 depression instrument.16 
Both incident and prevalent primary care cases of depression were included.  In line with the 
pragmatic nature of this trial, patients were eligible to participate whether or not they were in 
receipt of antidepressant medication or had co-morbid physical illness or non-psychotic functional 
disorders.  We excluded people currently in receipt of psychological therapy.   
We also excluded potential participants who: 
• were actively suicidal as identified by the Primary Care Physician or as reported by item 9 on 
the PHQ-9 
• had been bereaved within the last year 
• had given birth within the last year 
• had a diagnosis of psychotic depression 
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• had a primary diagnosis of alcohol or drug abuse 
• were not able to read and write in English 
 
Randomisation and masking 
Simple randomisation was performed using a computer-generated random number sequence.  At 
the end of the baseline appointment study researchers telephoned a secure randomisation line at 
the York Trials Unit and were given participant allocation and MoodGYM log-in details.  Participants 
were informed immediately’ 
 
Outcome measures 
Primary outcome measure: the pre-specified primary outcome was depression severity and 
symptomatology as measured on a validated self-report continuous measure (the Patient Health 
Questionnaire-9 (PHQ9))16 at four months. 
Secondary outcome measures: PHQ-9 at 12 months (as a continuous measure); PHQ-9 at 4 and 12 
months (dichotomous measure at cut-point PHQ9 >= 10);16 anxiety (GAD-7);18 somatoform 
complaints (PHQ-15);19 health-state utility (EuroQol - EQ5D); 20 service use using the adapted Client 
Service Receipt Inventory (CSRI)21 at four and 12 months. 
Sample size calculation: The REEACT-2 trial was powered on the basis of an ability to detect a 
between group difference in PHQ scores.  We sought to recruit 350 patients with depression - 175 
participants per arm.  The REEACT-2 trial was designed to have sufficient power to detect a Cohen’s 
d effect size of 0.30 with 80% power allowing for loss to follow up of 20% in line with our empirically-
based estimates from the REEACT trial.  The final sample size for the two arms was 369 and we 
exceeded this pre-specified sample size. 
 
Statistical analysis 
All outcomes were summarised descriptively by intervention group and at each time point using 
mean, median, standard deviation (SD), range and number of patients for continuous outcomes and 
number of patients and percentage for discrete outcomes.  The primary outcome was the severity of 
depression as measured by the Patient Health Questionnaire 9 (PHQ-9) as a continuous measure at 
four months.  Statistical analyses were performed in SAS version 9.3. 
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PHQ-9 as a continuous outcome:  The PHQ-9 score was summarised and analysed as a continuous 
outcome.  This was summarised for each assessment time point (baseline, four and 12 months) using 
mean, SD, median and range, and the number of missing values.  Plots were presented showing the 
mean and 95% CI at each time point.  A repeated measures mixed regression model was used to 
analyse the change in PHQ-9 score over time.  This included all randomised participants (intention to 
treat) and provides reliable estimates assuming the data are missing at random (MAR).  The 
outcome was the PHQ-9 score at four and 12 months and the model included the baseline PHQ-9 
score, treatment group, age, gender, baseline GAD-7 score and time.  The treatment x time 
interaction was included to evaluate if the difference between treatments changed over time.  The 
mean difference, 95% CI and p-values are presented for all terms in the model.  Effect sizes (Cohen’s 
d) were calculated for the between group differences in mean PHQ-9 score at four and 12 months 
using the difference between the means and corresponding standard errors from the mixed model.  
The standard errors were converted to standard deviations using the corresponding sample size in 
each treatment group. 
PHQ-9 as a dichotomous outcome: The dichotomous analysis (not depressed (PHQ-9 < 
10)/depressed (PHQ 9 ≥ 10)) compared minimally-supported cCBT with telephone-facilitated cCBT 
using a logistic regression model adjusting for the baseline PHQ-9 score, age, gender, baseline GAD-7 
score and treatment.  The dichotomous analysis was on a complete case basis (only including those 
with a four-month assessment).  A sensitivity analysis was performed using simple imputation and a 
worst case scenario.  This assumed that all participants with a missing outcome were still depressed 
with a PHQ-9 score ≥ 10. 
Other secondary outcomes:  GAD-7 and the PHQ-15 scores were analysed as continuous outcomes 
using the same repeated measures mixed models described for PHQ-9 above. 
Resource use data and health state utilities:  (derived from the EQ5D) formed the basis of a full 
economic evaluation and are described in the full study report.22 
Adherence: Adherence by participants to the computer programme was measured by requesting 
information from the website providing MoodGYM (hosted by the developers of MoodGYM at the 
Australian National University – ANU).  We obtained computer usage data on the number of times 
each participant logged on to the MoodGYM programme and whether each module was 25, 50, 75 
or 100 per cent complete. 
Adverse events:  were classified according to their seriousness and relationship to the intervention.  
 
 
 
10 
 
Role of the funding source 
This study was commissioned by the UK NIHR Health Technology Assessment Programme (project 
reference HTA 06/43/504).  The funder of this study had no role in study design, data collection, data 
analysis, data interpretation or writing of the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the decision to submit for publication. 
 
Results 
A total of 369 participants were randomised to the two-armed comparison of minimally-supported 
cCBT with telephone-facilitated cCBT, n=182 and n=187 respectively.  The first participant was 
randomised on the 24th June 2011 and the last on the 25th April 2013.  The flow of participants 
through the trial is shown in the CONSORT diagram (Figure 1). 
 
The two groups were well balanced at baseline for gender, age, ethnicity and education.  The mean 
age of participants was 40.6 years (sd13.8).  The study population was mostly white British (94%) 
and 64.5% were female.  The minimally-supported cCBT and telephone-facilitated cCBT groups were 
balanced at baseline for employment.  The majority (61.5%) of participants were employed and of 
these 23.6% were absent from work by reason of depression at the time of their baseline 
assessment (Table 1).  The severity of depression at baseline (as ascertained by the median PHQ9 
score) was 16 (range 10-25) which corresponds with a moderate to high level of severity.   
 
<Figure 1 about here> 
<Table 1 about here> 
 
PHQ-9 as a continuous outcome:  At the four month primary outcome the between-group 
difference in PHQ-9 scores was 1.9 points (95% CI 0.5 to 3.3) in favour of telephone-facilitated cCBT, 
with a standardised effect size (Cohen’s d) of 0.32 (p=0.009).  At 12 months there was no longer 
evidence of a between-group difference in PHQ-9 scores (0.9 95% CI -0.5 to 2.3).  Using a repeated 
measures analysis over the whole trial period the between-group difference in PHQ-9 scores was 1.4 
(95% CI 0.2 to 2.6) in favour of telephone-facilitated cCBT with a standardised effect size (Cohen’s d) 
of 0.27 (p=0.0253) (see figure 2 and table 2 & 3). 
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PHQ-9 as a dichotomous outcome: After four months 66 (50.30%) of the 128 participants in the 
minimally-supported cCBT group and 51 (36.2%) of the 141 in the telephone-facilitated cCBT group 
had a PHQ-9 score greater than or equal to 10.  The odds of no longer being depressed (defined as 
PHQ-9 < 10) at four months were increased twofold in the telephone-facilitated cCBT group 
compared to minimally supported cCBT (odds ratio [OR] 2.05 95% confidence interval [CI] 1.23 to 
3.42).  The benefit of telephone-facilitated cCBT was no longer significant at 12 months ([OR 1.63 
95% CI 0.98 to 2.71 p=0.06).  See table 2. 
<Figure 2 about here> 
<Table 2 & 3 about here> 
 
Other secondary outcomes:  For secondary outcomes there was a significant between group 
difference in anxiety scores (GAD-7) in favour of telephone-facilitated cCBT when all time points 
were considered (between group difference 1.2, 95% CI 0.1 to 2.3; p=0.037) (see figure 3 and table 
4).  For somatic complaints there was a borderline significant difference in favour of telephone–
facilitated cCBT when all time points were considered (between group difference 1.1, 95% CI 0.0 to 
1.8; p=0.051) (see figure 4 and table 5). 
 
<Figure 3 & 4 about here> 
<Table 4 & 5 about here> 
 
Adherence:  When computer records were scrutinised there were few participants who completed 
all five sessions in either minimally-supported (10.4%) or telephone-facilitated cCBT (19.4%).  Usage 
was generally increased by a factor of between 1.5 and two when telephone-facilitation was offered, 
with 46.2% of participants in receipt of telephone facilitation completing two or more sessions 
versus 29.1% of participants with minimal support.  See figure 5 and table 6 for a detailed summary 
of cCBT programme usage.   
 
<Figure 5 and table 6 about here> 
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Adverse events:  There were a total of ten serious adverse events, none of which was thought to be 
related to the trial.  All were reviewed by the Trial Steering Committee (TSC) and the Data 
Monitoring and Ethics Committee (DMEC). 
 
Discussion 
REEACT 2 is one of the largest trials of computer delivered CBT to date.  The trial tested whether the 
addition of structured telephone facilitation substantially increased engagement with computer-
mediated CBT and resulted in improved outcomes.  We purposely designed a pragmatic trial to test 
effectiveness under real world conditions rather than efficacy under ideal but restrictive conditions 
in order to maximise the external validity of our results.23  The main finding of the REEACT 2 trial is 
that the addition of structured telephone facilitation resulted in significant reductions in depression 
severity compared to cCBT with technical support alone.  The effect size was moderate and was 
most evident in the short term (4 months) and had diminished by 12 months.  Telephone facilitation 
of cCBT therefor expedited depression improvement, though the absence of benefit at 12 months is 
unsurprising given the average duration of an episode of depression is less than 12 months.  When 
depression was considered as a binary outcome, the odds of no longer being depressed were twice 
as high in the telephone facilitated group at 4 months.  Benefits in terms of psychological outcomes 
were also observed using a validated anxiety scale and for somatoform complaints when outcomes 
were averaged over a 12 month period.  Engagement with the technology was increased through the 
addition of telephone facilitation.   
The REEACT 2 trial drew upon a manualised form of telephone support, which can readily be 
delivered after a relatively brief period of training.  At present computerised CBT is offered by many 
healthcare systems as a minimally-supported low-intensity psychological intervention and as part of 
a stepped care framework.  The intervention trialed in the REEACT 2 study therefore represents an 
enhancement of care that can be readily delivered at scale in primary care settings.  The results of 
the REEACT 2 trial should be considered alongside other trials and systematic reviews of cCBT and 
low intensity interventions for common mental disorders.  Our earlier study (the REEACT trial)8 was 
similarly a large scale pragmatic trial of cCBT where one arm included the free to use cCBT package 
(MoodGYM).  In this previous trial we offered a low intensity form of technical telephone support 
and found that usage was low and there were no additional clinical benefits of cCBT when it was 
added to usual primary care.  This led us to speculate that an enhancement in the level of support 
and guidance might increase uptake and effectiveness.  Evidence that the addition of guidance to 
cCBT is associated with a greater level of effectiveness comes from systematic reviews, where 
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pooled estimates of the effect size of trials with therapist guidance are larger than the pooled effect 
size obtained from unsupported cCBT.10  Evidence also comes from a systematic review of small-
scale head to head comparisons of unsupported versus supported cCBT in a range of common 
mental disorders.15  This hypothesis has now been directly tested in the present randomised 
controlled trial which, to our knowledge, is the first test of this in a large scale (adequately-powered) 
direct randomised head-to-head comparison.  The results of the REEACT 2 trial are also comparable 
to other primary care based psychological treatments,24 but the effect size observed in REEACT 2 is 
smaller compared to other developer-led trials of cCBT.10  The additional benefit of guided support is 
in line with the results of a systematic review of three small scale studies in depression.15 
The REEACT 2 trial has several strengths in its design.  First the REEACT 2 trial was pragmatic in 
design and recruited from primary care, whereas most trials to date have recruited from online 
populations or by participant advertisement.  This addresses a major shortcoming of the literature 
identified by Andersson and Cuijpers in their 2009 review.10  The results of REEACT 2 are therefore 
more generalisable to clinical populations encountered in primary care.  Second, the trial was 
significantly larger than other trials to date (see Baumeister et al15) and had sufficient power to 
detect more modest effect sizes.  Third, we conducted a pragmatic trial of effectiveness rather than 
efficacy by trialling a low-intensity enhancement to cCBT that could be delivered at distance to a 
range of people fulfilling very broad depression inclusion criteria (typical of those encountered in 
primary care).  Fourth, the period of follow up was one year and this allows some conclusions to be 
drawn about the durability of effect.  Finally we were able to study the actual use of computer 
technology in our trial participants with reference to computer records.  
There were limitations to the REEACT 2 study.  First, in view of the pragmatic nature of the design 
there was loss to follow up of around one quarter of the participants overall, and we know very little 
about the outcomes of these participants.  Second, we did not measure outcome with a clinical 
interview to establish the presence of depression according to accepted classification systems.  
Instead we rely on self-report measures of depression severity; though these are well-validated 
against diagnostic systems.25  Third, even with the provision of telephone facilitation, only a small 
proportion of participants in either arm completed all sessions of the cCBT programme.  There is 
possibly more still that can be offered to enhance the uptake of computer therapy.  Finally the level 
of depression severity at baseline was moderate to high, and this is at the upper range of severity 
recommended in some stepped care systems.4  However the positive results of the REEACT 2 trial 
provide supportive evidence that low intensity interventions can be offered to this group and will 
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results in improved outcomes.  This finding is consistent with recent reviews of the effectiveness of 
low intensity interventions across the range of severities of depression.26 
The implications for practice and policy that emerge from the first REEACT and REEACT 2 trials are 
twofold.  The first is that minimally supported cCBT results in very low levels of uptake and confers 
little over usual care.  We would therefore suggest that healthcare systems do not offer this form of 
unsupported treatment as part of stepped care.  However unsupported cCBT should still be offered 
as a form of direct access treatment to non-clinical populations, though the benefits that might be 
expected are likely to be small.  The second implication is that the addition of structured telephone 
facilitation (such as that designed in REEACT 2 to work alongside MoodGYM) will result in greater 
levels of engagement with computer technology.  In turn this will produce moderate clinical 
improvements and reductions in the proportion of people who continue to experience depression 
over a 4 to 12 month period.  Telephone support is a low intensity enhancement of care that can be 
offered at scale and could be readily implemented in most healthcare settings as part of a stepped 
care system. 
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Figure 1: Consolidated standards of reporting trials (CONSORT) diagram  
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Figure 2:  Depression severity (mean and 95% CI PHQ-9 score*) at each assessment 
 
*Results from a repeated measures, mixed model adjusting for baseline score, age, gender, baseline 
GAD-7 score and time 
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Figure 3:  Anxiety severity (mean and 95% CI GAD7 score*) at each assessment 
 
*Results from a repeated measures, mixed model adjusting for baseline score, age, gender, and time 
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Figure 4:  Severity of somatoform complaints (mean and 95% CI PHQ15 score) at each 
assessment 
  
*Results from a repeated measures, mixed model adjusting for baseline score, age, gender, baseline 
GAD-7 score and time 
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Figure 5:  MoodGYM usage as ascertained by computer login records 
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Table 1: Baseline characteristics of randomised participants 
 Minimally-supported cCBT 
(n=182) 
Telephone-
facilitated cCBT 
(n=187) 
Total (n=369) 
SEX    
Female 113 (62.1%) 125 (66.8%) 238 (64.5%) 
PATIENT AGE (YEARS)    
Mean (SD) 40.3 (13.7) 41.0 (13.8) 40.6 (13.8) 
    
    
PREVIOUS EPISODES OF 
DEPRESSION WHEN HELP WAS 
SOUGHT? 
   
Yes 127 (69.8%) 134 (71.7%) 261 (70.7%) 
CURRENTLY TAKING 
MEDICATION FOR DEPRESSION 
   
Yes 71 (39.0%) 72 (38.5%) 143 (38.8%) 
No 111 (61.0%) 115 (61.5%) 226 (61.2%) 
    
Mean PHQ9 score (SD) 16.4 (4.1) 16.8 (3.9) 16.6 (4.0) 
Mean GAD7 score (SD) 14.1 (4.4) 14.5 (4.4) 14.3 (4.4) 
Mean PHQ15 score (SD) 11.5 (4.8) 11.9 (5.0) 11.7 (4.9) 
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Table 2:  Depression severity (PHQ-9 scores) at each time point 
 Baseline  Month 4  Month 12  
 Minimally-
supported 
Telephone-
facilitated 
Minimally-
supported 
Telephone-
facilitated 
Minimally-
supported 
Telephone-
facilitated 
PHQ-9 
continuous score 
      
Mean (SD) 16.4 (4.1) 16.8 (3.9) 10.4 (6.4) 8.5 (6.3) 9.2 (6.2) 8.2 (6.4) 
 Median 16 17 10 7 9 7 
  Range 10-25 10-26 0-27 0-24 0-25 0-27 
n 182 187 128 141 132 142 
PHQ-9 
dichotomised 
      
Depressed 
N (%) 
182 (100%) 187 (100%) 66 (51.6%) 51 (36.2%) 57 (43.2%) 46 (32.4%) 
Not depressed  
N (%) 
0 0 62 (48.4%) 90 (63.8%) 75 (56.8%) 96 (67.6%) 
Missing 0 0 54 (30%) 46 (25%) 50 (27%) 45 (24%) 
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Table 3: Between group differences in depression severity (PHQ9) at four and 12 months and 
mixed repeated measure across all time points 
Mean differences in PHQ-9 score 
Effect 
Cohen’s d 
effect size Estimate 
Lower 
95% CI 
Upper 
95% CI t Value p-value 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
Month 4 
0.324 -1.8923 -3.2969 -0.4877 2.65 0.0085 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
Month 12 
0.155 -0.9192 -2.3341 0.4957 1.28 0.2020 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
 (over all time points) 
0.274 -1.4057 -2.6336 
 
-0.1748 2.25 0.0253 
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Table 4: Between group differences in anxiety severity (GAD7) at four and 12 months and 
mixed repeated measure across all time points 
Mean differences in GAD-7 score 
Effect 
Cohen’s d 
effect size Estimate 
Lower 
95% CI 
Upper 
95% CI t Value p-value 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
Month 4 
0.236 -1.2291 -2.4374 0.1425 1.85 0.0659 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
Month 12 
0.166 -1.1269 -2.3122 0.1676 1.75 0.0819 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
 (over all assessments) 
0.255 -1.1780 -2.2813 -0.0747 2.10 0.0365 
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Table 5: Between group differences in severity of somatoform complaints (PHQ15) at four and 
12 months and mixed repeated measure across all time points 
Mean differences in PHQ-15 score 
Effect 
Cohen’s d 
effect size Estimate 
Lower 
95% CI 
Upper 
95% CI t Value p-value 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
Month 4 
0.121 -0.5088 -1.5701 0.5526 0.94 0.3460 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
Month 12 
0.300 -1.2410 -2.2692 -0.2127 2.38 0.0182 
Telephone-facilitated cCBT vs.  
minimally-supported cCBT 
 (over all assessments) 
0.303 -1.1099 -1.7521 0.0024 1.96 0.0506 
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Table 6:  MoodGYM usage data 
 Module 1 Module 2 Module 3 Module 4 
 Minimally-
supported 
Telephone-
facilitated 
Minimally-
supported 
Telephone-
facilitated 
Minimally-
supported 
Telephone-
facilitated 
Minimally-
supported 
Logged on 
but didn’t 
complete 
25% 
  7.1% 5.4% 6% 8.1% 1.1% 
25% 
complete 
1.6% 2.2% 2.2% 3.8% 2.7% 2.7%  
50% 
complete 
1.6% 2.2% 3.8% 3.8% 0.5% 4.3% 0.5% 
75% 
complete 
2.2% 4.8% 0.5% 3.8% 0.5% 1.1%  
100% 
complete 
45.1% 
 
 
64.5% 
 
 
29.1% 46.2% 
 
 
17.6% 28.5% 
 
 
14.3% 
 
